François-Clément Bidard, MD, PhD; William Jacot, MD, PhD; Nicolas Kiavue, MBBS; et al.
free access
JAMA Oncol. 2021;7(1):34-41. doi:10.1001/jamaoncol.2020.5660
This phase 3 randomized clinical trial assesses the efficacy of a clinician-driven treatment choice vs a circulating tumor cell count鈥揹riven choice for first-line treatment among women with hormone receptor鈥損ositive, ERBB2-negative metastatic breast cancer.
Ehab Atallah, MD; Charles A. Schiffer, MD; Jerald P. Radich, MD; et al.
free access
has audio
JAMA Oncol. 2021;7(1):42-50. doi:10.1001/jamaoncol.2020.5774
This nonrandomized clinical trial evaluates molecular recurrence and patient-reported outcomes after tyrosine kinase inhibitor discontinuation in US patients with chronic myeloid leukemia.
-
Audio Author Interview:
Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Michael S. Leapman, MD; Rong Wang, PhD; Shuangge Ma, PhD; et al.
free access
JAMA Oncol. 2021;7(1):52-58. doi:10.1001/jamaoncol.2020.6086
This dynamic cohort study evaluates the regional adoption of genomic testing for prostate cancer and the common trajectories of uptake shared by regions.
Veronica Mariotti, MD; Hyo Han, MD; Roohi Ismail-Khan, MD; et al.
free access
JAMA Oncol. 2021;7(1):61-69. doi:10.1001/jamaoncol.2020.5572
This randomized clinical trial evaluates clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane.
Masha J. Livhits, MD; Catherine Y. Zhu, MD; Eric J. Kuo, MD; et al.
free access
JAMA Oncol. 2021;7(1):70-77. doi:10.1001/jamaoncol.2020.5935
This randomized clinical trial compares the diagnostic performance between an RNA test and a DNA-RNA test in patients with thyroid nodules.
Emese Zsiros, MD, PhD; Sarah Lynam, MD; Kristopher M. Attwood, PhD; et al.
free access
JAMA Oncol. 2021;7(1):78-85. doi:10.1001/jamaoncol.2020.5945
This single-arm, phase 2 nonrandomized clinical trial assesses the efficacy and safety of combined pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide in women with recurrent platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Anna Marklund, MD; Frida E. Lundberg, PhD; Sandra Eloranta, PhD; et al.
open access
JAMA Oncol. 2021;7(1):86-91. doi:10.1001/jamaoncol.2020.5957
This cohort study investigates the long-term reproductive outcomes in women who did or did not undergo fertility preservation at the time of breast cancer diagnosis.
Eric J. Lehrer, MD, MS; Raj Singh, MD; Ming Wang, MS, PhD; et al.
free access
JAMA Oncol. 2021;7(1):92-106. doi:10.1001/jamaoncol.2020.6146
This meta-analysis reviews 21 trials of stereotactic ablative radiotherapy administered to patients with oligometastatic cancer.
Jules Lansu, MD; Judith V. M. G. Bovée, MD, PhD; Pètra Braam, MD, PhD; et al.
free access
online only
JAMA Oncol. 2021;7(1):e205865. doi:10.1001/jamaoncol.2020.5865
This nonrandomized controlled trial reports the oncological outcomes of the deintensification (from 50 Gy to 36 Gy) of a preoperative radiotherapy regimen for adults with myxoid liposarcoma.